(Q33328648)

25 July 2017

1 reference

title

Heparin-induced thrombocytopenia. (English)

1 reference

25 July 2017

1 reference

Kaplan KL

1

1 reference

25 July 2017

Francis CW

series ordinal

2

1 reference

25 July 2017

publication date

1 March 1999

1 reference

25 July 2017

1 reference

25 July 2017

volume

13

1 reference

25 July 2017

issue

1

1 reference

25 July 2017

page(s)

1-7

1 reference

Heparin-induced thrombocytopenia

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Arterial Embolism Occurring During Systemic Heparin Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Heparin-coated catheters and heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Prevention of thromboembolism as a cause of thromboembolic complications. A study of the incidence of heparin-induced thrombocytopenia type II

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216).

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Thrombocytopenia associated with low-molecular-weight heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Heparin-induced thrombocytopenia with thrombotic complications during prophylactic treatment with low-molecular-weight heparin.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Thrombosis during the use of the heparinoid Organon 10172 in a patient with heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

A 14-year study of heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Heparin-induced immune thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

The release, distribution, and clearance of human beta-thromboglobulin and platelet factor 4.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Binding of platelet factor 4 to cultured human umbilical vein endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Improved method for purification of human platelet factor 4 by affinity and ion-exchange chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Interaction of platelet factor 4 with human platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Structure and biology of proteoglycans

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Proteoglycans in haemopoietic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

The release of histamine and 5‐hydroxytryptamine (serotonin) from platelets by antigen‐antibody reactions (in vitro)

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Insights into heparin-induced thrombocytopenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Human platelet Fc receptor for immunoglobulin G. Identification as a 40,000-molecular-weight membrane protein shared by monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Heparin-associated thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Pathogenicity of human anti-platelet factor 4 (PF4)/heparin in vivo: generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Immune endothelial-cell injury in heparin-associated thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Specificity, pathogenecity, and clinical value of antiendothelial cell antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Induction of interleukin-1 and subsequent tissue factor expression by anti-proteinase 3 antibodies in human umbilical vein endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Platelet aggregation studies for the diagnosis of heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Heparin-induced platelet aggregation vs platelet factor 4 enzyme-linked immunosorbent assay in the diagnosis of heparin-induced thrombocytopenia-thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Heparin-induced thrombocytopenia and antithrombotic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Thrombolysis to treat arterial thrombotic complications of heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2899%2990018-8

7 January 2021

10.1016/S0268-960X(99)90018-8

Identifiers

DOI

1 reference

25 July 2017

1 reference